Data to be collected in this study
| Data | Description |
| Demographic data and other clinical profile data | Age, sex, nationality, place of residence (city or province), weight, height, declared history of exposure (international travel, community or domestic travel and hospital), smoking status, healthcare worker status and pregnancy status. |
| Comorbidities | Hypertension, diabetes mellitus, heart failure, coronary artery disease, chronic obstructive pulmonary disease, bronchial asthma, chronic kidney disease, chronic liver disease, obesity, malignancy, HIV and others. |
| Neurological history | Stroke/other cerebrovascular diseases, epilepsy, dementia, movement disorder, headache syndrome, CNS infection, PNS infection, central demyelinating syndrome, myelopathy, neuropathy, neuromuscular junction disorder, myopathy and others. |
| Respiratory and constitutional symptoms associated with COVID-19 | Any respiratory/constitutional symptoms, cough, rhinorrhoea, sputum production, sore throat, haemoptysis, dyspnoea, fever, fatigue, arthralgia, diarrhoea and myalgia; date of illness onset. |
| COVID-19 disease severity at nadir | Mild: defined as presence of mild pneumonia or absence of pneumonia; severe disease: defined as the presence of dyspnoea, respiratory rate >30 breaths/minute, hypoxia (SpO2 <93%) or >50% lung involvement on imaging within 24–48 hours; and critical disease: defined as the presence of respiratory failure, shock or multiorgan dysfunction. |
| Neurological symptoms | Any neurological symptom, headache, nausea, vomiting, seizure, altered sensorium, confusion, anosmia/hyposmia, blindness/decreased vision, eye pain, ophthalmoplegia/ophthalmoparesis, hearing loss/decreased hearing, dizziness, ageusia/dysgeusia, facial numbness, facial weakness, dysarthria, dysphonia, dysphagia, tongue weakness, neck weakness, extremity weakness, extremity numbness/paraesthesia, tremor, dystonia, choreoathetosis, bradykinaesia, ataxia, meningismus, myalgia and others; date of neurological symptom onset. |
| New-onset neurological disorders or complications | Any neurological complication, meningitis, encephalopathy, encephalitis, meningoencephalitis, anoxic/hypoxic brain syndrome, acute disseminated encephalomyelitis, acute necrotising haemorrhagic encephalopathy, any seizure disorder, acute symptomatic seizure, epilepsy, status epilepticus, any acute cerebrovascular disease (CVD), acute CVD (infarction), acute CVD (haemorrhagic), any movement disorder, movement disorders (hyperkinetic), movement disorders (hypokinetic), cerebellitis, optic neuritis, myelitis, sensory ganglionitis/dorsal radiculitis, anterior horn syndrome (polio-like syndrome)/ventral radiculitis, peripheral neuritis (GBS-like syndrome), peripheral neuritis (other than GBS-like syndrome), neuromuscular disorder, myositis and others; date of new neurological disorder or complication onset. |
| Imaging done | CT scan, MRI scan, affected portion/s of the neuroaxis in the imaging. |
| Cerebrospinal fluid (CSF) analysis | CSF total cell count, CSF neutrophil count, CSF lymphocyte count, CSF protein, CSF glucose, serum glucose, CSF COVID-19 test result and other CSF tests done. |
| Electrophysiological studies | Electroencephalography, and electromyography-nerve conduction studies tests, if done, and pertinent results. |
| Treatment given | Chloroquine, hydroxychloroquine, lopinavir+ritonavir, tocilizumab, remdesivir, systemic glucocorticoids, convalescent plasma and others; antibiotics given. |
| Neurological interventions | For example, antiplatelet, anticoagulant, antiepileptic drugs and others. |
| Mortality | Date of mortality and cause/s of mortality. |
| Respiratory failure | Date of respiratory failure onset, date of mechanical ventilator cessation and cause/s of respiratory failure. |
| ICU admission | Date of first day of ICU admission, date of discharge from ICU and indication/s for ICU admission. |
| Other neurological outcomes at discharge | Full neurological recovery: defined as patients with confirmed COVID-19 infection who had any neurological deficit during admission, who then had full neurological recovery with no noted neurological deficits at discharge; stable with improvement of neurological deficits: defined as patients with COVID-19 infection who had any neurological deficit during admission, who then had improvement but not complete resolution of the neurological deficits at discharge; stable with no improvement of neurological deficits: defined as the patients with COVID-19 infection who had any neurological deficit during admission, who then had no improvement of the neurological deficits at discharge |
| Final disposition | Discharged stable/recovered, home against medical advice, transferred to other hospital, died/mortality; date of hospital discharge. |
CNS, central nervous system; GBS, Guillain-Barre syndrome; ICU, intensive care unit; PNS, peripheral nervous system; SpO2, peripheral capillary oxygen saturation.